Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Convertible Debt (2018 - 2024)

Historic Convertible Debt for Karyopharm Therapeutics (KPTI) over the last 7 years, with Q1 2024 value amounting to $171.1 million.

  • Karyopharm Therapeutics' Convertible Debt rose 48.21% to $171.1 million in Q1 2024 from the same period last year, while for Mar 2024 it was $171.1 million, marking a year-over-year increase of 48.21%. This contributed to the annual value of $170.9 million for FY2023, which is 47.85% up from last year.
  • Karyopharm Therapeutics' Convertible Debt amounted to $171.1 million in Q1 2024, which was up 48.21% from $170.9 million recorded in Q4 2023.
  • In the past 5 years, Karyopharm Therapeutics' Convertible Debt registered a high of $171.1 million during Q1 2024, and its lowest value of $111.8 million during Q1 2020.
  • Moreover, its 5-year median value for Convertible Debt was $169.5 million (2022), whereas its average is $156.9 million.
  • Its Convertible Debt has fluctuated over the past 5 years, first skyrocketed by 5093.99% in 2021, then skyrocketed by 46.65% in 2022.
  • Karyopharm Therapeutics' Convertible Debt (Quarter) stood at $117.9 million in 2020, then soared by 43.56% to $169.3 million in 2021, then grew by 0.48% to $170.1 million in 2022, then grew by 0.48% to $170.9 million in 2023, then increased by 0.12% to $171.1 million in 2024.
  • Its Convertible Debt stands at $171.1 million for Q1 2024, versus $170.9 million for Q4 2023 and $170.7 million for Q3 2023.